Table 2.
Description of the autoimmune liver disease group
| Autoimmune hepatitis (AIH) | n=11 |
| Female, n (%) | 10 (91) |
| Age (years), median (range) | 50 (20–70s) |
| Peak LFTs at liver biopsy, median (range) | |
| ALT (U/l) | 757 (165–3301) |
| AST/ALT | 0.7 (0.2–1.1) |
| Total bilirubin (µmol/l) | 54 (10–388) |
| Serological markers of AIH | |
| Increased IgG, n (%) | 9 (82) |
| ANA >1/80, n (%) | 10 (91) |
| SMA >1/80 (%), n (%) | 10 (91) |
| Positive anti-actin antibodies, n (%) | 10 (91) |
| Patients with a history of extra-hepatic autoimmunity* | 6 (55) |
| Primary biliary cholangitis (PBC) | n=3 |
| Female, n (%) | 3 (100) |
| Age (years), median (range) | 46 (40–60s) |
| Peak LFT at liver biopsy, median (range) | |
| Alkaline phosphatase (U/l) | 250 (240–330) |
| Gamma-GT (U/l) | 167 (101–339) |
| ALT (U/l) | 74 (49–80) |
| AST/ALT | 0.6 (0.6–0.8) |
| Total bilirubin (µmol/l) | 7 (5–11) |
| Serological markers of PBC | |
| Anti-mitochondria antibodies, n (%) | 3 (100) |
| Anti-M2 antibodies, n (%) | 3 (100) |
| Patients with a history of extrahepatic autoimmunity† | 2 (66) |
*Extrahepatic autoimmunity: Graves’ disease (2/11), autoimmune thyroiditis (1/11), DRESS syndrome (1/11), lymphocytic colitis (1/11), rheumatoid arthritis (1/11), type 1 diabetes mellitus (1/11).
†Extrahepatic autoimmunity: Rheumatoid arthritis (2/3).
AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ANA, anti-nuclear antibody; AST, aspartate aminotransferase; Gamma-GT, gamma-glutamyl transferase; irAE, immune-related adverse event; LFT, liver function tests; SMA, smooth muscle antibody.